Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.
Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.
复制标题
前列腺素 F2 α-1-异丙酯多次给药可维持高眼压和青光眼患者眼内压的降低。
DOI：
10.1016/s0161-6420(89)32717-5
复制
发表时间：
1989
期刊：
影响因子：
13.7
通讯作者：
Bito,LZ
中科院分区：
文献类型：
--
作者：
Camras,CB;Siebold,EC;Lustgarten,JS;Serle,JB;Frisch,SC;Podos,SM;Bito,LZ
在一项随机、双盲、安慰剂对照研究中，0.25 μg（n = 11）或0.5 μg（n = 13）前列腺素F2α-1-异丙酯（PGF 2 α-IE）局部应用于高眼压症或慢性开角型青光眼患者的一只眼睛，每日两次，持续8天。与对侧溶剂处理眼相比，PGF 2 α-IE显著（P< 0.05）降低眼内压（IOP），从首次0.5 μg给药后4小时开始，持续至第14次给药后至少12小时，在两种剂量治疗的最后一天，平均降低4 - 6 mmHg，持续显著（P< 0.005）。未观察到对侧效应。对于0.5 μg剂量，PG治疗眼的平均张力描记术流出功能显著（P< 0.05）高于溶剂治疗眼（分别为0.17 ± 0.02和0.12 ± 0.01 μl/min/mmHg; ±平均值的标准误）。结膜充血在应用PGF 2 α-IE后30至60分钟达到最大值。一些患者报告在一些剂量后持续几分钟的轻度刺激。视力、屈光度、瞳孔直径、房水闪光、前房细胞反应、Schirmer试验、脉率和血压均无显著改变。本研究结果表明，PGF_（2 α）-IE是一种有效的眼内扩张剂，是一种很有前途的青光眼治疗药物。
In a randomized, double-masked, placebo-controlled study, 0.25 μg (n = 11) or 0.5 μg (n = 13) of prostaglandin F2α-1-isopropyl ester (PGF2α-IE) was applied topically twice daily for 8 days to one eye of ocular hypertensive or chronic open-angle glaucoma patients. Compared with contralateral, vehicle-treated eyes, PGF2α-IE significantly (P< 0.05) reduced intraocular pressure (IOP), beginning 4 hours after the first 0.5-μg dose and lasting at least 12 hours after the fourteenth dose, with a significant (P< 0.005) mean reduction of 4 to 6 mmHg maintained throughout the last day of therapy with either dose. A contralateral effect was not observed. Mean tonographic outflow facility was significantly (P< 0.05) higher in PG-treated compared with vehicle-treated eyes (0.17 ± 0.02 versus 0.12 ± 0.01 μl/minute/mmHg, respectively; ± standard error of the mean) for the 0.5-μg dose. Conjunctival hyperemia reached a maximum at 30 to 60 minutes after PGF2α-IE application. Some patients reported mild irritation lasting several minutes after some doses. Visual acuity, accommodative amplitude, pupillary diameter, aqueous humor flare, anterior chamber cellular response, Schirmer's test, pulse rate, and blood pressure were not significantly altered. Our findings show that PGF2α-IE is a potent ocular hypotensive agent and a promising drug for glaucoma therapy.